Oncolytic virus therapy for cancer

References

• XiaZJChangJHZhangLPhase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagusAi Zheng2004231216661670 Chinese15601557
   PubMedGoogle Scholar
• YamamotoMCurielDTCancer gene therapyTechnol Cancer Res Treat20054431533016029053
   PubMed Web of Science ®Google Scholar
• HuebnerRJRoweWPSchattenWESmithRRThomasLBStudies on the use of viruses in the treatment of carcinoma of the cervixCancer1956961211121813383455
   PubMed Web of Science ®Google Scholar
• GaggarAShayakhmetovDMLiszewskiMKAtkinsonJPLieberALocalization of regions in CD46 that interact with adenovirusJ Virol200579127503751315919905
   PubMed Web of Science ®Google Scholar
• SirenaDLilienfeldBEisenhutMThe human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3J Virol20047894454446215078926
   PubMed Web of Science ®Google Scholar
• KrasnykhVDmitrievIMikheevaGMillerCRBelousovaNCurielDTCharacterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knobJ Virol1998723184418529499035
   PubMed Web of Science ®Google Scholar
• DmitrievIKashentsevaERogersBEKrasnykhVCurielDTEctodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cellsJ Virol200074156875688410888627
   PubMed Web of Science ®Google Scholar
• YamamotoMDavydovaJWangMInfectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancerGastroenterology200312541203121814517802
   PubMed Web of Science ®Google Scholar
• TakayamaKReynoldsPNShortJJA mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropismVirology2003309228229312758175
   PubMed Web of Science ®Google Scholar
• DouglasJTRogersBERosenfeldMEMichaelSIFengMCurielDTTargeted gene delivery by tropism-modified adenoviral vectorsNat Biotechnol19961411157415789634824
   PubMed Web of Science ®Google Scholar
• CurielDTStrategies to adapt adenoviral vectors for targeted deliveryAnn N Y Acad Sci199988615817110667212
   PubMed Web of Science ®Google Scholar
• TanakaTHuangJHiraiSCarcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectorsClin Cancer Res200612123803381316778108
   PubMed Web of Science ®Google Scholar
• LiHJEvertsMYamamotoMCurielDTHerschmanHRCombined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumorsCancer Res200969255456419147569
   PubMed Web of Science ®Google Scholar
• BischoffJRKirnDHWilliamsAAn adenovirus mutant that replicates selectively in p53-deficient human tumor cellsScience199627452863733768832876
   PubMed Web of Science ®Google Scholar
• HeiseCSampson-JohannesAWilliamsAMcCormickFVon HoffDDKirnDHONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsNat Med1997366396459176490
   PubMed Web of Science ®Google Scholar
• MarxJOncology. Recruiting the cell’s own guardian for cancer therapyScience200731558161211121317332387
   PubMed Web of Science ®Google Scholar
• O’SheaCCJohnsonLBagusBLate viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivityCancer Cell20046661162315607965
   PubMed Web of Science ®Google Scholar
• RodriguezRSchuurERLimHYHendersonGASimonsJWHendersonDRProstate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cellsCancer Res19975713255925639205053
   PubMed Web of Science ®Google Scholar
• AlemanyRBalagueCCurielDTReplicative adenoviruses for cancer therapyNat Biotechnol200018772372710888838
   PubMed Web of Science ®Google Scholar
• CurielDTThe development of conditionally replicative adenoviruses for cancer therapyClin Cancer Res2000693395339910999720
   PubMed Web of Science ®Google Scholar
• GuedanSRojasJJGrosAMercadeECascalloMAlemanyRHyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growthMol Ther20101871275128320442708
   PubMed Web of Science ®Google Scholar
• JinFXieZKuoCJChungLWHsiehCLCotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapyCancer Gene Ther200512325726715565180
   PubMed Web of Science ®Google Scholar
• GuptaVWangWSosnowskiBAHofmanFMChenTCFibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cellsNeurosurg Focus2006204E2616709032
   PubMedGoogle Scholar
• SethPWangZGPisterADevelopment of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapyHum Gene Ther200617111152116017032151
   PubMed Web of Science ®Google Scholar
• ShashkovaEVKuppuswamyMNWoldWSDoroninKAnticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Ther2008152617217992200
   PubMed Web of Science ®Google Scholar
• GreenNKHerbertCWHaleSJExtended plasma circulation time and decreased toxicity of polymer-coated adenovirusGene Ther200411161256126315215884
   PubMed Web of Science ®Google Scholar
• DoroninKShashkovaEVMaySMHofherrSEBarryMAChemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusHum Gene Ther200920997598819469693
   PubMed Web of Science ®Google Scholar
• HengstschlagerMKnoflerMMullnerEWOgrisEWintersbergerEWawraEDifferent regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cellsJ Biol Chem19942691913836138428188661
   PubMed Web of Science ®Google Scholar
• McCartJAWardJMLeeJSystemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genesCancer Res200161248751875711751395
   PubMed Web of Science ®Google Scholar
• ThorneSHHwangTHO’GormanWERational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963J Clin Invest2007117113350335817965776
   PubMed Web of Science ®Google Scholar
• ColamoniciORDomanskiPSweitzerSMLarnerABullerRMVaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signalingJ Biol Chem19952702715974159787608155
   PubMed Web of Science ®Google Scholar
• KimJHLeeYSKimHHuangJHYoonARYunCORelaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacyJ Natl Cancer Inst200698201482149317047197
   PubMedGoogle Scholar
• SymonsJAAlcamiASmithGLVaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificityCell19958145515607758109
   PubMed Web of Science ®Google Scholar
• KirnDHThorneSHTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNat Rev Cancer200991647119104515
   PubMed Web of Science ®Google Scholar
• ThorneSHHwangTHKirnDHVaccinia virus and oncolytic virotherapy of cancerCurr Opin Mol Ther20057435936516121702
   PubMedGoogle Scholar
• KirnDHWangYLe BoeufFBellJThorneSHTargeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virusPLoS Med2007412e35318162040
   PubMed Web of Science ®Google Scholar
• LiuTCHwangTParkBHBellJKirnDHThe targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinomaMol Ther20081691637164218628758
   PubMed Web of Science ®Google Scholar
• ParkBHHwangTLiuTCUse of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialLancet Oncol20089653354218495536
   PubMed Web of Science ®Google Scholar
• GuoZSNaikAO’MalleyMEThe enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2Cancer Res200565219991999816267024
   PubMed Web of Science ®Google Scholar
• DranoffGJaffeeELazenbyAVaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunityProc Natl Acad Sci U S A1993908353935438097319
   PubMed Web of Science ®Google Scholar
• FilipazziPValentiRHuberVIdentification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony- stimulation factor-based antitumor vaccineJ Clin Oncol200725182546255317577033
   PubMed Web of Science ®Google Scholar
• BronteVTsungKRaoJBIL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastasesJ Immunol199515410528252927730632
   PubMed Web of Science ®Google Scholar
• RaoJBChamberlainRSBronteVIL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expressionJ Immunol19961569335733658617961
   PubMed Web of Science ®Google Scholar
• KaufmanHLFlanaganKLeeCSPerrettaDJHorigHInsertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicityVaccine20022013–141862186911906776
   PubMed Web of Science ®Google Scholar
• HodgeJWSabzevariHYafalAGGritzLLorenzMGSchlomJA triad of costimulatory molecules synergize to amplify T-cell activationCancer Res199959225800580710582702
   PubMed Web of Science ®Google Scholar
• HodgeJWHigginsJSchlomJHarnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenVaccine200927334475448219450631
   PubMed Web of Science ®Google Scholar
• Kudo-SaitoCHodgeJWKwakHKim-SchulzeSSchlomJKaufmanHL4-1BB ligand enhances tumor-specific immunity of poxvirus vaccinesVaccine200624234975498616621183
   PubMed Web of Science ®Google Scholar
• KaufmanHLDeraffeleGMitchamJTargeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaJ Clin Invest200511571903191215937544
   PubMed Web of Science ®Google Scholar
• KaufmanHLCohenSCheungKLocal delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumorsHum Gene Ther200617223924416454657
   PubMed Web of Science ®Google Scholar
• FarassatiFYangADLeePWOncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1Nat Cell Biol20013874575011483960
   PubMed Web of Science ®Google Scholar
• PanWBodempudiVEsfandyariTFarassatiFUtilizing ras signaling pathway to direct selective replication of herpes simplex virus-1PLoS One200948e651419652721
   PubMed Web of Science ®Google Scholar
• LiuBLRobinsonMHanZQICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Ther200310429230312595888
   PubMed Web of Science ®Google Scholar
• IkedaKIchikawaTWakimotoHOncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responsesNat Med19995888188710426310
   PubMed Web of Science ®Google Scholar
• CurrierMAGillespieRASawtellNMEfficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamideMol Ther200816587988518388918
   PubMed Web of Science ®Google Scholar
• FulciGBreymannLGianniDCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProc Natl Acad Sci U S A200610334128731287816908838
   PubMed Web of Science ®Google Scholar
• KaurBBratDJDeviNSVan MeirEGVasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factorOncogene200524223632364215782143
   PubMed Web of Science ®Google Scholar
• KurozumiKHardcastleJThakurROncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61Mol Ther20081681382139118545226
   PubMed Web of Science ®Google Scholar
• CantinCHolgueraJFerreiraLVillarEMunoz-BarrosoINewcastle disease virus may enter cells by caveolae-mediated endocytosisJ Gen Virol200788Pt 255956917251575
   PubMed Web of Science ®Google Scholar
• KellyEJHadacEMGreinerSRussellSJEngineering microRNA responsiveness to decrease virus pathogenicityNat Med200814111278128318953352
   PubMed Web of Science ®Google Scholar
• FiolaCPeetersBFournierPArnoldABucurMSchirrmacherVTumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defenceInt J Cancer2006119232833816470838
   PubMed Web of Science ®Google Scholar
• SchirrmacherVHaasCBoniferRAhlertTGerhardsRErtelCHuman tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virusGene Ther199961637310341877
   PubMed Web of Science ®Google Scholar
• ApostolidisLSchirrmacherVFournierPHost mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional applicationInt J Oncol20073151009101917912426
   PubMed Web of Science ®Google Scholar
• WildenHFournierPZawatzkyRSchirrmacherVExpression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virusInt J Oncol200934497198219287954
   PubMed Web of Science ®Google Scholar
• CsataryLKGosztonyiGSzeberenyiJMTH-68/H oncolytic viral treatment in human high-grade gliomasJ Neurooncol2004671–2839315072452
   PubMed Web of Science ®Google Scholar
• CsataryLKBakacsTUse of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastomaJAMA1999281171588158910235150
   PubMed Web of Science ®Google Scholar
• ElankumaranSRockemannDSamalSKNewcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell deathJ Virol200680157522753416840332
   PubMed Web of Science ®Google Scholar
• HrabakACsukaIBajorTCsataryLKThe cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitroCancer Lett2006231227928916399229
   PubMed Web of Science ®Google Scholar
• LorenceRMRoodPAKelleyKWNewcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicityJ Natl Cancer Inst19888016130513122459402
   PubMed Web of Science ®Google Scholar
• SchirrmacherVBaiLUmanskyVYuLXingYQianZNewcastle disease virus activates macrophages for anti-tumor activityInt J Oncol200016236337310639582
   PubMed Web of Science ®Google Scholar
• UmanskyVShatrovVALehmannVSchirrmacherVInduction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa BInt Immunol1996844914988671635
   PubMed Web of Science ®Google Scholar
• de LeeuwOSKochGHartogLRavenshorstNPeetersBPVirulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase proteinJ Gen Virol200586Pt 61759176915914855
   PubMed Web of Science ®Google Scholar
• HuangZPandaAElankumaranSGovindarajanDRockemannDDSamalSKThe hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulenceJ Virol20047884176418415047833
   PubMed Web of Science ®Google Scholar
• KimSHSubbiahMSamuelASCollinsPLSamalSKRoles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxovirusesJ Virol201185178582859621680512
   PubMed Web of Science ®Google Scholar
• Romer-OberdorferAVeitsJWernerOMettenleiterTCEnhancement of pathogenicity of Newcastle disease virus by alteration of specific amino acid residues in the surface glycoproteins F and HNAvian Dis200650225926316863077
   PubMed Web of Science ®Google Scholar
• ZamarinDPalesePOncolytic Newcastle disease virus for cancer therapy: old challenges and new directionsFuture Microbiol20127334736722393889
   PubMed Web of Science ®Google Scholar
• FournierPBianHSzeberenyiJSchirrmacherVAnalysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulationMethods Mol Biol201279717720421948477
   PubMedGoogle Scholar
• BianHWildenHFournierPPeetersBSchirrmacherVIn vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter proteinInt J Oncol20062961359136917088973
   PubMed Web of Science ®Google Scholar
• BaiLKoopmannJFiolaCFournierPSchirrmacherVDendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patientsInt J Oncol200221468569412239606
   PubMed Web of Science ®Google Scholar
• PhuangsabALorenceRMReichardKWPeeplesMEWalterRJNewcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administrationCancer Lett20011721273611595126
   PubMed Web of Science ®Google Scholar
• SchirrmacherVGriesbachAAhlertTAntitumor effects of Newcastle disease virus in vivo: local versus systemic effectsInt J Oncol200118594595211295039
   PubMed Web of Science ®Google Scholar
• FournierPZengJSchirrmacherVTwo ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNAInt J Oncol200323367368012888903
   PubMed Web of Science ®Google Scholar
• WashburnBSchirrmacherVHuman tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosisInt J Oncol2002211859312063554
   PubMed Web of Science ®Google Scholar
• WashburnBWeigandMAGrosse-WildeATNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virusJ Immunol200317041814182112574346
   PubMed Web of Science ®Google Scholar
• BucklandFEBynoeMLTyrrellDAExperiments on the spread of colds. II. Studies in volunteers with coxsackievirus A21J Hyg (Lond)19656333273435318065
   PubMedGoogle Scholar
• CouchRBCateTRGeronePJProduction of illness with a small-particle aerosol of coxsackie A21J Clin Invest19654453554214278169
   PubMed Web of Science ®Google Scholar
• SpickardAEvansHKnightVJohnsonKAcute respiratory disease in normal volunteers associated with Coxsackie A-21 viral infection. III. Response to nasopharyngeal and enteric inoculationJ Clin Invest19634284085213990087
   PubMed Web of Science ®Google Scholar
• MiyamotoSInoueHNakamuraTCoxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinomaCancer Res201272102609262122461509
   PubMed Web of Science ®Google Scholar
• ErringtonFSteeleLPrestwichRReovirus activates human dendritic cells to promote innate antitumor immunityJ Immunol200818096018602618424722
   PubMed Web of Science ®Google Scholar
• BenenciaFCourregesMCConejo-GarciaJRHSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerMol Ther200512578980215925544
   PubMed Web of Science ®Google Scholar
• ZhangYChirmuleNGaoGPAcute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophagesMol Ther200135 Pt 169770711356075
   PubMed Web of Science ®Google Scholar
• PichlmairAReis e SousaCInnate recognition of virusesImmunity200727337038317892846
   PubMed Web of Science ®Google Scholar
• JablonskaJLeschnerSWestphalKLienenklausSWeissSNeutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor modelJ Clin Invest201012041151116420237412
   PubMed Web of Science ®Google Scholar
• PrestwichRJErringtonFIlettEJTumor infection by oncolytic reovirus primes adaptive antitumor immunityClin Cancer Res200814227358736619010851
   PubMed Web of Science ®Google Scholar
• NormanKLHirasawaKYangADShieldsMALeePWReovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infectionProc Natl Acad Sci U S A200410130110991110415263068
   PubMed Web of Science ®Google Scholar
• GoldenJWLinkeJSchmechelSThoemkeKSchiffLAAddition of exogenous protease facilitates reovirus infection in many restrictive cellsJ Virol200276157430744312097555
   PubMed Web of Science ®Google Scholar
• MarcatoPShmulevitzMPanDStoltzDLeePWRas transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent releaseMol Ther20071581522153017457318
   PubMed Web of Science ®Google Scholar
• AlainTKimTSLunXProteolytic disassembly is a critical determinant for reovirus oncolysisMol Ther20071581512152117519890
   PubMed Web of Science ®Google Scholar
• SmakmanNvan den WollenbergDJBorel RinkesIHHoebenRCKranenburgOSensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3DJ Virol20057923149811498516282499
   PubMed Web of Science ®Google Scholar
• AdairRARoulstoneVScottKJCell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsSci Transl Med20124138138ra177
   Web of Science ®Google Scholar
• NormanKLCoffeyMCHirasawaKReovirus oncolysis of human breast cancerHum Gene Ther200213564165211916487
   PubMed Web of Science ®Google Scholar
• AlainTHirasawaKPonKJReovirus therapy of lymphoid malignanciesBlood2002100124146415312393565
   PubMed Web of Science ®Google Scholar
• HirasawaKNishikawaSGNormanKLAlainTKossakowskaALeePWOncolytic reovirus against ovarian and colon cancerCancer Res20026261696170111912142
   PubMed Web of Science ®Google Scholar
• HingoraniPZhangWLinJLiuLGuhaCKolbEASystemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenograftsCancer201111781764177421472724
   PubMed Web of Science ®Google Scholar
• WilcoxMEYangWSengerDReovirus as an oncolytic agent against experimental human malignant gliomasJ Natl Cancer Inst2001931290391211416111
   PubMedGoogle Scholar
• KilaniRTTamimiYHanelEGSelective reovirus killing of bladder cancer in a co-culture spheroid modelVirus Res200393111212727337
   PubMed Web of Science ®Google Scholar
• EtohTHimenoYMatsumotoTOncolytic viral therapy for human pancreatic cancer cells by reovirusClin Cancer Res2003931218122312631628
   PubMed Web of Science ®Google Scholar
• LokenSDNormanKHirasawaKNodwellMLesterWMDemetrickDJMorbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeuticCancer Biol Ther20043873473815197356
   PubMed Web of Science ®Google Scholar
• ConnollyJLRodgersSEClarkePReovirus-induced apoptosis requires activation of transcription factor NF-kappaBJ Virol20007472981298910708412
   PubMed Web of Science ®Google Scholar
• ClarkePMeintzerSMSpaldingACJohnsonGLTylerKLCaspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infectionOncogene200120476910691911687970
   PubMed Web of Science ®Google Scholar
• ClarkePTylerKLDown-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosisApoptosis200712121122317136319
   PubMed Web of Science ®Google Scholar
• SmakmanNvan der BiltJDvan den WollenbergDJHoebenRCBorel RinkesIHKranenburgOImmunosuppression promotes reovirus therapy of colorectal liver metastasesCancer Gene Ther200613881581816543920
   PubMed Web of Science ®Google Scholar
• ThirukkumaranCMLuiderJMStewartDABiological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autograftsBone Marrow Transplant200535111055106415821774
   PubMed Web of Science ®Google Scholar
• QiaoJWangHKottkeTCyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusClin Cancer Res200814125926918172278
   PubMed Web of Science ®Google Scholar
• RussellSJPengKWBellJCOncolytic virotherapyNat Biotechnol201230765867022781695
   PubMed Web of Science ®Google Scholar
• CattaneoRMiestTShashkovaEVBarryMAReprogrammed viruses as cancer therapeutics: targeted, armed and shieldedNat Rev Microbiol20086752954018552863
   PubMed Web of Science ®Google Scholar
• MastrangeloMJMaguireHCJrEisenlohrLCIntratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanomaCancer Gene Ther19996540942210505851
   PubMed Web of Science ®Google Scholar
• KimJHOhJYParkBHSystemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSFMol Ther200614336137016905462
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature201147773629910221886163
   PubMed Web of Science ®Google Scholar
• ParatoKABreitbachCJLe BoeufFThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther201220474975822186794
   PubMed Web of Science ®Google Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol200927345763577119884534
   PubMed Web of Science ®Google Scholar
• OckertDSchirrmacherVBeckNNewcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinomaClin Cancer Res19962121289816085
   PubMed Web of Science ®Google Scholar
• KarcherJDyckhoffGBeckhovePAntitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cellsCancer Res200464218057806115520216
   PubMed Web of Science ®Google Scholar
• SteinerHHBonsantoMMBeckhovePAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefitJ Clin Oncol200422214272428115452186
   PubMed Web of Science ®Google Scholar
• HaasCLuleiMFournierPArnoldASchirrmacherVA tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytesInt J Cancer2006118365866716108015
   PubMed Web of Science ®Google Scholar
• AuGGLinczLFEnnoAShafrenDROncolytic coxsackievirus A21 as a novel therapy for multiple myelomaBr J Haematol2007137213314117391493
   PubMed Web of Science ®Google Scholar
• BerryLJAuGGBarryRDShafrenDRPotent oncolytic activity of human enteroviruses against human prostate cancerProstate200868657758718288643
   PubMed Web of Science ®Google Scholar
• ShafrenDRAuGGNguyenTSystemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21Clin Cancer Res2004101 Pt 1536014734451
   PubMed Web of Science ®Google Scholar
• SkeldingKABarryRDShafrenDRSystemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21Breast Cancer Res Treat20091131213018256929
   PubMed Web of Science ®Google Scholar
• SkeldingKABarryRDShafrenDREnhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochlorideInvest New Drugs4201230256858121170760
   PubMed Web of Science ®Google Scholar
• AuGGBeagleyLGHaleyESBarryRDShafrenDROncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18Virol J201182221241513
   PubMed Web of Science ®Google Scholar